Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

Redx to present Preclinical Data on Novel Bacterial Topoisomerase Inhibitors at ASM Microbe 2016 Conference
17 June 2016

preview image of Redx Poster SU-463, ASM Microbe 2016

Redx Pharma Plc is pleased to announce that it will present data on its novel bacterial topoisomerase inhibitors (NBTIs) at the inaugural annual American Society for Microbiology (ASM) Microbe 2016 conference taking place from 16-20 June in Boston, Massachusetts.

Both the rise of antimicrobial resistance and the current antibiotic innovation gap have highlighted the need for novel antimicrobial agents, particularly for the treatment of Gram-negative bacterial infections. Redx is making promising progress in meeting this need following its discovery of a series of NBTIs that demonstrate broad-spectrum antibacterial activity against ESKAPE pathogens and low potential for resistance development.

Redx will be presenting the in vitro biological properties of its NBTIs, including activity against multi-drug resistant strains, preliminary assessment of safety profile and data on the in vivo exposure level of representative compounds.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

In The Media

12 August 2016
Redx Pharma featured in a campaign to showcase the North of England life science offer to global markets…


13 July 2016
Proactive Investors speaks to Cantor Fitzgerald about its latest valuation of Redx Pharma…

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details